New drug combo aims to shrink kidney tumors before surgery
NCT ID NCT07516366
First seen Apr 19, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This early-phase trial tests whether giving two immunotherapy drugs (botensilimab and balstilimab) before surgery is safe and helps shrink high-risk kidney cancers that haven't spread. About 16 adults with clear cell renal cell carcinoma will receive the drugs, then have their kidney tumor removed. The goal is to see if this approach can improve outcomes without causing major delays or side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.